Most people think of biotech as speculative – a domain of lottery tickets and roulette-type wagers on FDA decisions. But real success here is different than that. The work lies in telling the difference between potential winners and a roll of the dice. Tech Investor editor Erez Kalir explains.
This giant, household name of a company was trading at a rare discount to its intrinsic value. Despite generating extraordinary levels of free cash flow, maintaining global search dominance, and aggressively buying back stock, the market had mispriced it. We did not. Shares soared 81% since then!
Kicking off Porter & Co.’s 12 Days Of Christmas series, Distressed Investing senior analyst Marty Fridson shares a big win on both the distressed bonds and distressed equities of a midwest ethanol producer, following Marty’s “topping off” strategy.
Complete Investor is the culmination of everything Porter has done and learned in his nearly three decades as a financial publisher. There is so much in store in 2026 – to make you a better investor, to make you a complete investor, and to make you a much wealthier investor.
Today, Porter completes the report-card grading of the Porter & Co. financial publications with the final three of our remaining advisories – Porter & Co.’s Asymmetry, The Trading Club, and Porter’s Permanent Portfolio.
Today, we continue the Porter’s report-card grading with two of our key advisories… Marty Fridson’s Distressed Investing and Erez Kalir’s Tech Frontiers.
Today, Porter kicks off his annual Report Card grading with Porter Stansberry’s Complete Investor – and the new spin-off Best Buys.